Hims and HersFDA warningletter The FDA has issued significant warning letters to companies in October 2025 concerning peptides, particularly those related to GLP-1 agonists like semaglutide and tirzepatide.FDA Issues Warning Letters Against Online GLP-1 Sellers These enforcement actions highlight the U2026年1月21日—Telehealth. All American Wellness.Warning LetterIssued 09/09/2025. Amazing Meds.Warning LetterIssued 09/09/2025..S. Food and Drug Administration's increasing scrutiny of unapproved drugs, compounded substances, and misleading marketing practices within the rapidly growing peptide marketWarning Letters. The FDA's focus on these FDA peptides warning letters 2025 October indicates a broader trend of regulatory oversight aimed at ensuring drug safety and efficacy.
A significant portion of the FDA's recent enforcement activities has targeted companies illegally selling unapproved drugs containing peptides such as semaglutide, tirzepatide, and retatrutide. These substances are often falsely labeled for "research use only" or marketed as legitimate alternatives to FDA-approved medications. The agency has issued numerous warning letters to manufacturers and compounders, emphasizing that these products have not undergone the rigorous safety and efficacy evaluations required for human use. For instance, the FDA has specifically warned companies over compounded retatrutide, underscoring the risks associated with products that bypass standard approval processes.
The FDA's concerns extend to compounded drugs containing peptides like CJC-1295, which may pose risks of immunogenicity depending on the route of administration and present complexities in manufacturing.作者：AE Mattei·2025—Teriparatide is one of several genericpeptidesnamed in a recent Food and Drug Administration (FDA) guidance (FDA-2017-D-5767-0002), ... Companies are being alerted to these potential issues, with the agency demanding written responses within a strict timeframe, typically 15 working days, to address the violations cited in the warning letters.
The GLP-1 receptor agonists, widely sought for weight loss and diabetes management, have been a major focusFDA's Overreach on Compounded Peptides: Legal Battles .... The FDA has sent warning letters to over 50 GLP-1 drug compounders and manufacturers in September 2025Healthcare, Food and Drug Administration (FDA .... This surge in enforcement reflects the explosion in the availability of compounded versions of these drugs, despite prior warnings from the FDA. Beyond GLP-1s, the FDA is also expanding its oversight to include a broader range of peptides.2025年1月16日—This e-alert is part of a series of e-alerts summarizing publicly availableFDAenforcement letters (ie,warning lettersand untitled letters) Import Alert 66-78 has been updated to include additional unapproved peptides, signaling a comprehensive approach to regulating this sector.Other safety alerts - 2026-01-14 (1)
Companies like All American Wellness and Amazing Meds have received warning letters, as noted in recent inspection and recall updates, for violations that often include manufacturing infractions and the online sale of unapproved or counterfeit weight-loss medications. The FDA's enforcement actions can escalate to seizures of products, injunctions, and consent decrees, which can ultimately lead to the shutdown of a businessFDA Alert: Endocrinology Drug News Roundup 2025.
FDA warning letters are formal communications from the agency to individuals or organizations found to be in violation of federal laws or regulations. These letters detail the nature of the violation, cite the relevant statutes and regulations, and specify the actions required to correct the deficiency.2025年11月14日—During the COVID-19 pandemic, theFDAissued over a half-dozenwarning lettersto businesses promotingpeptideswith “immune-boosting powers. For drug-related violations, common issues include adulteration, misbranding, manufacturing practice violations (CGMP), and illegal promotion or sale of unapproved drugs2026年1月14日—FDAis requesting that drug application holders remove information regarding the risk of suicidal ideation and behavior (SI/B) from the labeling ....
The FDA's Office of Prescription Drug Promotion (OPDP) also issues untitled letters, which are another form of enforcement action targeting misleading or promotional content. The increase in CDER warning letters, reported as being up 50% in FY 2025, indicates a heightened level of regulatory activity and stricter scrutiny across the pharmaceutical industry.
For consumers, the FDA's actions serve as a critical reminder to be wary of products, especially peptides, marketed for therapeutic purposes that have not received FDA approval. The "research use only" labeling is a common tactic used to circumvent regulations, and consumers should exercise extreme caution when encountering such products. The availability of compounded drugs, while sometimes offering alternatives, also carries inherent risks, particularly when sourced from unregulated or foreign entities.The FDA Is Expanding Its Oversight: Research Use Only ...
Businesses operating in the peptide and pharmaceutical space must remain vigilant about compliance2026年1月21日—Telehealth. All American Wellness.Warning LetterIssued 09/09/2025. Amazing Meds.Warning LetterIssued 09/09/2025.. Understanding the nuances of FDA regulations, particularly concerning compounding, advertising, and manufacturing, is paramount. Proactive engagement with regulatory requirements, transparent practices, and a commitment to product safety are essential to avoid the severe consequences associated with FDA enforcement actions, including warning letters, product recalls, and potential business closure. The ongoing trend of FDA peptides warning letters in 2025 underscores the critical importance of adhering to regulatory standards to ensure public health and safety.FDA Advertising and Promotion Enforcement Activities
Join the newsletter to receive news, updates, new products and freebies in your inbox.